ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1689

Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy

Lihi Eder1, Xianwei Li2, Sydney Thib3, Darshini Ganatra4, Liqun Diao2 and Vinod Chandran5, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 3Women’s College Research Institute, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Biomarkers, immunology, Psoriatic arthritis, Spondyloarthropathies, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: To characterize the relationships between peripheral blood immune cell profiles in patients with psoriatic arthritis (PsA) and (1) baseline clinical and imaging disease features; (2) response to targeted advanced therapies at 3 months.

Methods: Patients with PsA who were initiating treatment with advanced therapies for active peripheral musculoskeletal disease were recruited. Patients were examined and ultrasound was performed to assess the level of inflammation in various PsA domains at baseline and after 3 months of treatment. Mass cytometry (CyTOF) was performed to characterize immune cell populations in whole blood. The frequencies of 16 immune cell populations (among CD3+ positive cells) were automatically quantified using Probability State Modelling algorithms. Hierarchical clustering was performed using immune cell population data. The association between the 3 identified immune cell clusters and baseline characteristics, as well as clinical and sonographic response to treatment, was assessed using GEE regression models.

Results: 40 treatment periods involving 34 patients were analyzed (21 IL-17i; 16 TNFi; 3 JAKi). 60% of patients achieved ACR20 response. Cluster analysis identified 3 immune clusters (Figure 1). Cluster 1 (γδT cells and CD8+ naïve predominant) was associated with lower sonographic inflammation, lower physician global assessment and younger age. Cluster 2 (Central Memory (CM) and Effector Memory (EM) CD4+ T cells predominant) was associated with the highest levels of sonographic inflammation, in particular synovitis and enthesitis scores, and older age. Cluster 3 (CD4+ and CD8+ Terminal Effector (TE) T cells and Th1 predominant) was associated with highest levels of peritenon inflammation (Figure 1B-C). Immune cell profiles were associated with clinical and sonographic response to therapy. Being in Cluster 2 was associated with a lower probability of achieving ACR20 response and with an increase in Disease Activity index for PsA (DAPSA) score compared to clusters 1 and 3 (Table 1). Among individual cell populations, higher levels of CD8+ cells, in particular naïve cells, was associated with reduction in DAPSA. Higher levels of γδT cells was associated with higher chances of achieving ACR20 response, while higher levels of naïve EM and CM CD4+ and Th1 cells were associated with lower treatment response (Table 1). The levels of Th1 and γδT cells also predicted change in sonographic inflammatory score (Figure 2).

Conclusion: Immune cell profiling can improve PsA phenotyping. CD4+ memory and Th1cells correlated with more severe synovitis and enthesitis and poor response to advanced therapies, while γδT cells and CD8+ naïve cells were associated with milder disease phenotype and improved treatment response.

Supporting image 1

Figure 1. Hierarchical cluster analysis of CD3+ immune cell populations finds 3 immune clusters (1A). Immune clusters show differences in sonographic features (1B), but fewer differences in clinical features (1C). *p<0.05

Supporting image 2

Table 1: The association between baseline immune profile* and clinical response to targeted advanced therapies at 3 months – GEE regression model (N=40)

Supporting image 3

Figure 2 – The association between immune cell populations and change in sonographic inflammation score by GEE model adjusted for baseline sonographic score


Disclosures: L. Eder: AbbVie, 2, 5, Eli Lilly, 2, 5, Fresenius Kabi, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sandoz, 5, UCB, 2, 5; X. Li: None; S. Thib: None; D. Ganatra: None; L. Diao: None; V. Chandran: AbbVie, 1, 5, 6, Amgen, 1, 5, 6, AstraZeneca, 3, Bristol-Myers Squibb (BMS), 1, 6, Eli Lilly, 1, 5, 6, Janssen, 1, 6, Novartis, 1, 1, 6, UCB, 1, 2.

To cite this abstract in AMA style:

Eder L, Li X, Thib S, Ganatra D, Diao L, Chandran V. Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/deep-cellular-immune-profiling-in-psoriatic-arthritis-correlates-with-imaging-phenotypes-and-response-to-targeted-advanced-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deep-cellular-immune-profiling-in-psoriatic-arthritis-correlates-with-imaging-phenotypes-and-response-to-targeted-advanced-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology